The downregulation of MTA3 was reported in breast cancer, endometrial cancer and ovarian cancer [15]–[17], while the upregulation of MTA3 expression has been implicated in human chorionic cancer [21]. This evidence concerns the gene MTA3 and endometrial cancer.